The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance
- 3.5k Downloads
Ectonucleotidases are ectoenzymes that hydrolyze extracellular nucleotides to the respective nucleosides. Within the past decade, ectonucleotidases belonging to several enzyme families have been discovered, cloned and characterized. In this article, we specifically address the cell surface-located members of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase/CD39) family (NTPDase1,2,3, and 8). The molecular identification of individual NTPDase subtypes, genetic engineering, mutational analyses, and the generation of subtype-specific antibodies have resulted in considerable insights into enzyme structure and function. These advances also allow definition of physiological and patho-physiological implications of NTPDases in a considerable variety of tissues. Biological actions of NTPDases are a consequence (at least in part) of the regulated phosphohydrolytic activity on extracellular nucleotides and consequent effects on P2-receptor signaling. It further appears that the spatial and temporal expression of NTPDases by various cell types within the vasculature, the nervous tissues and other tissues impacts on several patho-physiological processes. Examples include acute effects on cellular metabolism, adhesion, activation and migration with other protracted impacts upon developmental responses, inclusive of cellular proliferation, differentiation and apoptosis, as seen with atherosclerosis, degenerative neurological diseases and immune rejection of transplanted organs and cells. Future clinical applications are expected to involve the development of new therapeutic strategies for transplantation and various inflammatory cardiovascular, gastrointestinal and neurological diseases.
Keywordsapyrase brain CD39 ecto-ATPase immunology ischemia kidney liver nervous tissue NTPDase platelet vasculature
apyrase conserved regions
basic fibroblast growth factor
ecto-nucleoside triphosphate diphosphohydrolase
extracellular regulated kinase
focal adhesion kinase
nucleoside triphosphate diphosphohydrolase
platelet derived growth factor
ran binding protein
Extracellular nucleotides modulate a multiplicity of tissue functions including development, blood flow, secretion, inflammation and immune reactions. Indeed, signaling via extracellular nucleotides has been recognized for over a decade as one of the most ubiquitous intercellular signaling mechanisms [1, 2]. Essentially every cell in a mammalian organism leaks or releases these mediators, and carries receptors for nucleotides of which seven ionotropic (P2X) and at least eight metabotropic (P2Y) receptor subtypes have been identified and characterized to date. Whereas P2X receptors respond to ATP, P2Y receptors can be activated by ATP, ADP, UTP, UDP, ITP, and nucleotide sugars, albeit agonist specificity varies between subtypes and the multiple animal species . Depending on the P2 receptor subtype and signaling pathways involved, these receptors trigger and mediate short-term (acute) processes that affect cellular metabolism, adhesion, activation or migration. In addition, purinergic signaling also has profound impacts upon other more protracted responses, including cell proliferation, differentiation and apoptosis, such as seen in atherosclerosis, degenerative neurological diseases and in several inflammatory conditions [2, 4, 5].
The effects of extracellular nucleotides appear to overlap, at least in part, with those of vascular growth factors, cytokines (inflammatory), adhesion molecules and nitric oxide (NO). Nucleotide-mediated activation may be also synergistic with polypeptide growth factors (PDGF, bFGF) and insulin, the signaling being mediated via phospholipase C and D, diacylglycerol, protein kinase C, ERKs, phosphatidylinositol 3-kinases (PI3K), MAP kinases (MAPK) and Rho [6, 7, 8]. The situation concerning extracellular nucleotide-signaling can be suitably contrasted with the unique specificity of peptide hormones or vasoactive factors for often single, defined receptors [9, 10]. Within purinergic/pyrimidinergic signaling events specificity is dictated by three essential modulatory components: 1) The derivation or source of the extracellular nucleotides [1, 11, 12]; 2) the expression of specific receptors for these molecular transmitters (and for the nucleotide and nucleoside derivatives) [13, 14, 15, 16] (See also Molecular Recognition Section of National Institutes of Health, http://mgddk1.niddk.nih.gov/ also http://www.ensembl.org/index.html and http://www.geocities.com/bioinformaticsweb/speciesspecificdatabases.htm), and, 3) select ectonucleotidases that dictate the cellular responses by the stepwise degradation of extracellular nucleotides to nucleosides [17, 18, 19, 20].
Ensembles of ectonucleotidases, associated receptors and signaling molecules
Within the past decade, ectonucleotidases belonging to several enzyme families have been discovered, cloned and functionally characterized by pharmacological means. Specifically, we refer here to members of the ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase) family (EC 126.96.36.199) as ectoenzymes that hydrolyze extracellular nucleoside tri-and diphosphates and have a defined pharmacological profile. Most notably, in many tissues and cells, NTPDases comprise dominant parts of a complex cell surfacelocated nucleotide hydrolyzing and interconverting machinery. This ensemble includes the ecto-nucleotide pyrophosphatase phosphodiesterases (E-NPPs), NADglycohydrolases, CD38/NADase, alkaline phosphatases, dinucleoside polyphosphate hydrolases, adenylate kinase, nucleoside diphosphate kinase, and potentially ecto-F1-Fo ATP synthases [21, 22, 23, 24, 25] that may interact in various tissues and cellular systems.
The ectonucleotidase chain or cascade, as initiated by NTPDases can be terminated by ecto-5′-nucleotidase (CD73; EC 188.8.131.52) with hydrolysis of nucleoside monophosphates . Together, ecto-5′-nucleotidase and adenosine deaminase (ADA; EC 184.108.40.206), another ectoenzyme that is involved in purine salvage pathways and converts adenosine to inosine, closely regulate local and pericellular extracellular and plasma concentrations of adenosine [10, 27].
Several of these ectonucleotidase families and additional functions of NTPDases [28, 29, 30] are addressed elsewhere in this issue in detail. This review focuses on the surface-located mammalian members of the E-NTPDase protein family. It starts with a brief introduction of molecular structure and functional properties, followed by an analysis of the physiological and pathophysiological roles at various sites with an emphasis on vasculature and neural tissues.
Molecular identities unraveled
The literature on the molecular and functional characterization of the E-NTPDase family has been intensively reviewed [18, 19, 20, 21, 22, 31, 32, 33, 34, 35, 36] and will not be repeated here in detail. Our intent is to summarize principal properties of the enzymes that will be of use for the reader new to this field.
Nomenclature of mammalian members of the E-NTPDase family and chromosomal localization
Gene name human, mouse
Chromosome location human, mouse
Accession number human, mouse
14q24, 12E (12D1)a
10q24, 19D1 (19C3)a
The presence of ATP and/or ADP hydrolyzing activity at the surface of many cell types had been recognized for several decades [17, 37, 38, 39, 40]. However, the molecular identity of the first member of the ENTPDase family (NTPDase1) was not unraveled and determined until the mid-1990s. The prototypic member of the enzyme family had first been cloned and sequenced as a lymphocyte cell activation (CD39) antigen of undetermined function . Final success came from three independent approaches. Handa and Guidotti  purified and cloned a soluble ATP diphosphohydrolase (apyrase) from potato tubers and noted that this protein was related not only to similar enzymes of some protozoans, plants and yeast but also to human CD39. They also recognized conserved sequence domains and the relation to members of the actin-hsp70-hexokinase superfamily. This was then followed by the functional expression of human CD39 and the demonstration that this protein was in fact an ecto-apyrase . In parallel, ectonucleotidases (termed ATP diphosphohydrolases) from porcine pancreas and bovine aorta were purified. The partial amino acid sequences for both ATP diphosphohydrolases revealed identity with the cloned cDNA sequence of CD39 . The cDNA was isolated from human endothelial cells and functional, thromboregulatory studies confirmed that the dominant vascular ectonucleotidase (ATP diphosphohydrolase) activity was identical to the previously described and cloned human CD39 . Several internal peptide sequences obtained from the purified human placental ATP diphosphohydrolase  revealed that in retrospect this protein was also identical to CD39.
It was originally thought that there existed a single ectonucleotidase of the NTPDase type with potential post-translational modifications . However, a close molecular relative was soon cloned that revealed functional properties of an ecto-ATPase (now NTPDase2) rather than of an ecto-ATP diphosphohydrolase [47, 48]. Further human genomic analysis of expressed sequence tags (ESTs) allowed the identifi-cation of additional members of the gene family [49, 50, 51]. These genes were originally named CD39L(ike)1 to CD39L4. Then followed the identification, cloning and functional expression of all members of the ENTPDase family, the last to date being NTPDase8 .
Potential splice variants have been isolated for the surface-located NTPDase1 and NTPDase2 [for references see 34, 53]. It should be further noted that heterologous expression of potential splice variants does not necessarily result in the formation of a functional protein .
The initially proposed nomenclature  has been somewhat confusing as it did not meet with generally accepted norms for human cell differentiation molecules . While CD39 (now NTPDase1) indeed belongs to the cluster of differentiation antigens, CD39L1 (NTPDase2), CD39L3 (NTPDase3), CD39L4 (NTPDase5) and CD39L2 (NTPDase6) do not. Scientists at the Second International Workshop on Ecto-ATPases proposed that all E-NTPDase family members be termed as NTPDase proteins and classi-fied in order of discovery and characterization [34, 56]. The CD39 nomenclature should fall away for all but the prototypic member NTPDase1 that already has a long history of use in the Immunology and Oncology fields. Further revisions are however inevitable.
Membrane-bound NTPDase1 hydrolyzes ATP almost directly to AMP with the transient production of minor amounts of free ADP (Fig. 2). This functional property largely circumvents activation of P2Y-receptors for nucleoside diphosphates. Interestingly, significant amounts of UDP are accumulated when UTP is hydrolyzed by NTPDase1 . In contrast, ADP is released upon ATP hydrolysis by NTPDase2, then accumulates and is slowly dephosphorylated to AMP. On the one hand, this results in the removal of agonists for nucleoside triphosphate-sensitive P2Y-receptors (Fig. 2). On the other hand, it generates agonists for nucleoside diphosphate-sensitive receptors such as platelet P2Y1 and P2Y12 receptors . The actions of NTPDase3 and NTPDase8 result in intermediate patterns of product formation, leading to a transient accumulation of diphosphonucleosides with the simultaneous presence of triphosphonucleosides.
Principal structural features
The hallmarks of all NTPDases are the five highly conserved sequence domains known as ‘apyrase conserved regions’, abbreviated and termed ACR1 to ACR5 [42, 63, 64] that are involved in the catalytic cycle. This notion is supported by a considerable variety of deletion and mutation experiments [for reviews see 30, 34, 64, 65, 66, 67, 68].
NTPDases readily form homo-oligomeric assemblies. NTPDase1 to NTPDase3 were found as dimers to tetramers [29, 64, 73, 74, 75, 76, 77, 78]. In contrast to the P2X receptors that share a similar membrane topography, hetero-oligomeric complexes between NTPDases have not been reported, to date. Oligomeric forms reveal increased catalytic activity [73, 75, 76] and the state of oligomerization can affect catalytic properties [77, 78].
NTPDase1,2,3, and 8 are firmly anchored to the membrane via two transmembrane domains that in the instance of NTPDase1 are important for maintaining catalytic activity and substrate specificity [29, 64, 79]. The two transmembrane domains interact both within and between monomers. They may also undergo coordinated motions during the process of nucleotide binding and hydrolysis [29, 61]. This could in turn induce conformational changes  involving movement of the two major domains (I and II) relative to each other (Fig. 3). Alterations in quarternary structure and subunit interactions may thus affect the impact or interaction of ACRs involved in substrate binding and hydrolysis. Whether posttranslational modifications such as protein phosphorylation contribute to this dynamic behavior remains to be investigated.
Biologically active NTPDase1 is subject to differential forms of surface modification under conditions of oxidative stress that inhibit enzymatic activity, as influenced by unsaturated fatty acids [81, 82]. It also undergoes limited proteolysis that increases enzyme activity and differential glycosylation reactions that appear to be required for membrane expression . Since the surface-located ATP-hydrolyzing members of the NTPDase family pass through the endoplasmic reticulum and Golgi apparatus, the associated catalytic activity might abrogate ATP-dependent luminal functional processes. NTPDase1 becomes catalytically active on reaching the cell surface and glycosylation reactions appear crucial in this respect .
The N-terminal intracytoplasmic domain of NTPDase1 is palmitoylated. Truncated forms of NTPDase1 lacking the N-terminal intracytoplasmic region and the associated Cys13 residue, are not subject to palmitoylation. This post-translational modification appears to be constitutive and to contribute to the integral membrane association of this ectonucleotidase in lipid rafts [84, 85, 86]. This raises the possibility that NTPDase1 may be recycled to and from cell membranes via sequential actions of putative palmitoyltransferases and palmitoyl-protein thioesterases , in order to fine tune and modulate purinergic signaling responses. In contrast to NTPDase1 and NTPDase3, NTPDase2 does not have the required intra-cytoplasmic Cys to undergo this post-translational modification. The potential multimerization of NTPDase1  may be facilitated by acylation with intermolecular interactions within the cholesterol and sphingolipid-rich microdomains of the plasma membrane . Experiments using endothelial cells from caveolin-1 deficient mice suggest that caveolae are not essential for the enzymatic activity or for the targeting to the plasma membrane of NTPDase1. However, cholesterol depletion results in a strong inhibition of the enzyme . The targeting of palmitoylated NTPDase1 to lipid rafts could influence defined G-protein coupled receptors within this plasmalemmal microenvironment and thus regulate cellular signal transduction pathways. Furthermore, the caveolar co-localization of ecto-5′-nucleotidase, P2 receptors, and NTPDase1 could serve to modulate signaling via both ATP and adenosine at the cell surface and possibly also within endosomal compartments .
Transcriptional regulation of expression
Members of the E-NTPDase family are constitutively expressed in many tissues. To date, there is only scattered evidence on promoters and the factors controlling NTPDase expression . The transcription of NTPDase1/CD39 is constitutive in venous, arterial and certain non-fenestrated microvascular endothelium and certain immune cells e.g., B cells, dendritic cells and defined T-cell subsets [20, 89]. The modulated expression of NTPDase1 has been closely associated with inflammatory cytokines, oxidative stress and hypoxia in vitro and in vivo [19, 90].
Expression of NTPDase1 is increased in differentiating melanomas followed by a gradual decrease with tumor progression  and enhanced NTPDase1 activity of stimulated endothelial and mesangial cells is downregulated by glucocorticosteroids . Activity of ‘ecto-ATP diphosphohydrolase’ in human endothelial cells in-vitro is increased by aspirin  and glomerular ‘ecto-ATP diphosphohydrolase’ immunoreactivity might well be modulated by estradiol .
Transcription of NTPDase2 in mouse hepatoma cells is inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) . These cells contain both constitutive and TCDD-inducible NTPDase2 activity. The NTPDase2 core promotor reveals constitutive activity that is independent of TCDD . TCDD does not increase expression of NTPDase1, NTPDase3 or other ectonucleotidases and apparently fails to induce NTPDase2 in a variety of other cell lines derived from varying species . In rat Sertoli cells, NTPDase2 is upregulated by follicle-stimulating hormone and cAMP  and it is selectively downregulated in biliary cirrhosis . Human epidermoid carcinoma cells increase the cascade for extracellular nucleotide hydrolysis when periodically treated with extracellular ATP, suggesting that the substrate itself may affect the expression of its own hydrolysis chain .
A considerable number of compounds alter and inhibit extracellular nucleotide hydrolysis by NTPDases. These include non-hydrolysable nucleotide analogues and inhibitors of P2 receptors. Ideally, NTPDase inhibitors should not be P2 receptor agonists or antagonists and not be subject to dephosphorylation by the ectoenzyme [22, 101, 102]. The only commercially available compound reported to effectively inhibit hydrolysis of ATP in a variety of tissues without significantly acting on purinoceptors is the structural analogue of ATP, ARL 67156 (FPL 67156) (6-N, N-diethyl-D-β,γ-dibromomethylene ATP) [103, 104, 105]. Other potential inhibitors include 8-thiobutyladenosine 5′-triphosphate (8-BuS-ATP)  and 1-naphthol-3, 6-disulfonic acid (BG0136) . Periodate-oxidized ATP inhibits ecto-ATPase activity in 1312N1 human astrocytoma cells  and Gadolinium ions have been found to effectively inhibit the ecto-nucleoside triphosphate diphosphohydrolase from Torpedo electric organ as well as potato apyrase .
It is noteworthy that the potency of inhibitors can vary considerably between individual members of the E-NTPDase family [109, 110, 111]. This necessitates a functional evaluation of each inhibitor for the enzyme investigated in a given tissue or cell type. The failure to develop specific inhibitors remains a major impediment to ongoing discoveries.
Principal functional contexts
Cell surface-located NTPDases are considered to be of major importance for controlling the availability of extracellular nucleotide agonists at P2 receptors. They also contribute to recycling of nucleosides derived from extracellular nucleoside phosphates and metabolic salvage pathways. The number of studies that define a functional impact of individual NTPDases in purinergic signaling in situ is limited and has been dependent to date on global genetic modifications of mice and swine to delete or upregulate the NTPDase or P2 gene of interest . Subtype-specific inhibitors, siRNA approaches, and animals in which the encoding gene can be inactivated or selectively induced in specific tissues will be of major importance.
There is increasing experimental evidence that ectonucleotidases compete with P2 receptors for a limited pool of endogenously released nucleotide [112, 113] and —by hydrolyzing released nucleotide —terminate or modulate the function of P2 receptors [114, 115, 116]. Portal fibroblasts regulate P2Y receptormediated bile duct epithelial proliferation via expression of NTPDase2  (see liver section, below). NTPDases functionally interact with P2Y-receptors  and may also co-localize with these G-proteincoupled receptors (GPCR) in lipid rafts and possibly caveolae [118, 119, 120, 121]. The modulatory effects of NTPDases are complex as the enzymes differentially regulate agonist availability in a process that is dependent upon P2 receptor subtype by either degrading ATP/UTP or by generating ADP/UDP (Fig. 2).
Recent experiments suggest that plasma membranebound NTPDases may have functions distinct from their catalytic properties alone. In a yeast two-hybrid system using techniques developed by Zhong for yeast apyrases , the N-terminus of human NTPDase1 (used as bait protein) has been shown to interact with truncated Ran Binding Protein M (RanBPM, otherwise known as RanBP9, NM_005493) in the human library screened [122a]. RanBPM contains conserved SPRY (repeats in splA and RyR) domains that appear to be crucial for the interaction with NTPDase1 and is preferentially distributed in human heart tissues . RanBPM is known to interact with Sos and regulate ERK/Ras signaling. NTPDase1 interacts with RanBPM to directly modulate Ras activation and cellular proliferation in liver regeneration following partial hepatectomy .
The N-termini of NTPDases also have consensus sequences for protein phosphorylation by protein kinase C  that could have additional functional impacts. Furthermore, the C-terminal sequence of NTPDase1 contains a putative PDZ domain (-K-DM-V). This may have utility in determining interactions with select P2Y receptors e.g., the purinergic P2Y1 and P2Y2 receptors that terminate in -D-T-S-L and -D-I-R-L, respectively . PDZ domains are most often found in combination with other protein interaction domains (for instance, SH3, PTB, WW), participating in complexes that facilitate signaling or determine the localization of receptors [126, 127, 128].
Finally, the general membrane topography of NTPDase1 and oligomeric assembly resemble the morphology of channel forming proteins such as P2X nucleotide receptors and members of the epithelial Na+ channel/degenerin gene superfamily . This raises the question whether, in addition to their catalytic activity, NTPDases could function as channels. Release of ATP from Xenopus oocytes induced by hyperpolarizing pulses requires functional ecto-ATPase activity . To what extent this functional property is shared by the structurally related NTPDase2, NTPDase3 and NTPDase8 has not been investigated.
The normal vascular endothelium provides a barrier that separates blood cells and plasma factors from highly reactive elements of the deeper layer of vessel wall. The vessel wall maintains blood fluidity and promotes flow by inhibiting coagulation, platelet activation and promoting fibrinolysis . These properties are governed by important thromboregulatory mechanisms; key biological activities of the vasculature have been already identified and shown to be ecto-nucleotide catalysts that generate the respective nucleosides by phosphohydrolysis [19, 82]. The dominant ectonucleotidases of the vasculature have now more fully been characterized as NTPDases. This important biological property expressed by the endothelium and associated cells is responsible for the regulation of extracellular and plasma levels of nucleotides [20, 44, 82, 132, 133].
NTPDase1 is the major ectonucleotidase in the vasculature . Other NTPDases associated with the vasculature are the cell-associated NTPDase2 and the soluble monocyte expressed NTPDase5 [32, 50, 137]. The phosphohydrolytic reaction of NTPDase1 limits the platelet activation response that is dependent upon the paracrine release of ADP and activation of specific purinergic receptors [81, 132, 138]. In contrast, NTPDase2, a preferential nucleoside triphosphatase, activates platelets by converting the competitive antagonist (ATP) of platelet ADP-receptors to the specific agonist of the P2Y1, and P2Y12 receptors. In keeping with these biochemical properties, NTPDase1 is dominantly expressed by endothelial cells and the associated vascular smooth muscle where it serves as a thromboregulatory factor. In contrast, NTPDase2 is associated with the adventitial surfaces of the muscularized vessels, microvascular pericytes of some tissues and organs as the heart and the stromal cells and would potentially serve as a hemostatic factor .
Extracellular nucleotide stimulation of P2 receptors represents components of platelet, endothelial cell and leukocyte activation that culminate in vascular thrombosis and inflammation in vivo . In these inflammatory settings, with oxidant endothelial injury, NTPDase1 biochemical function is substantially, albeit temporarily, decreased because of post-translational changes; reconstitution of vascular NTPDase activity occurs following transcriptional upregulation of CD39 in endothelium [82, 139]. This functional change may relate, at least in part, to alterations in acylation and associated membrane lipid association with consequent disruption of multimer structure. Interestingly, palmitate supplementation may protect against loss of NTPDase activity following cellular activation in vitro . These observations may provide several avenues of research to augment NTPDase activity within the vasculature at sites of injury .
Mechanisms of endothelial cell activation by nucleotides
ATP and UTP increases intracellular calcium levels, results in cytoskeletal rearrangements and stimulates phosphorylation of several proteins in human endothelial cells (EC) that are also associated with integrin signaling [140, 141, 142]. These include the focal adhesion kinase (FAK) and paxillin, proline-rich tyrosine kinase 2 (Pyk2) (also named related adhesion focal tyrosine kinase, RAFTK) and p38 MAP kinase. Further, UTP preferentially increases EC migration in a PI3-kinase and ERK-dependent manner. Moreover, extracellular nucleotide-mediated EC activation involves cytoskeletal rearrangements and increases in cell motility, comparable to that seen with ligation of integrins by extracellular matrix proteins . These phenotypic changes (seen in both nucleotide-and matrix-mediated activation) are associated with tyrosine phosphorylation of FAK, paxillin and p130 Crk-associated substrate (p130cas) and down-stream activation of p38 MAP kinases. FAK has been implicated to play an important role in integrin-mediated signal transduction pathways , suggesting that P2-receptors are implicated in ‘inside-out’ integrin signaling in EC, as well as platelets [20, 112].
To test how extracellular nucleotide-mediated signaling influences pathophysiological events, several techniques have been developed and validated to manipulate NTPDase1 expression in the vasculature and to study conditions of inflammatory stress. The first mutant mouse derived and studied concerned the global deletion of the gene encoding the dominant ectonucleotidase NTPDase1 (Entpd1,cd39). The mutant mice exhibit major perturbations of P2 receptormediated signaling in the vasculature and immune systems [19, 89, 145]. These phenomena manifest as hemostatic defects, thromboregulatory disturbances, heightened acute inflammatory responses with a failure to generate cellular immune responses that are all associated with vascular endothelium, monocyte, dendritic cell and platelet integrin dysfunction [20, 112, 134].
The therapeutic potential of NTPDase1 to regulate P2 receptor function in the vasculature and mitigate against thrombotic/inflammatory stress has been further established by the generation of NTPDase1 transgenic mice and swine [20, 146], the use of adenoviral vectors to upregulate NTPDase1 in cardiac grafts  and the use of soluble derivatives of NTPDase1 and apyrases [133, 148]. The beneficial effects of administered NTPDases have been determined in several animal models of vascular inflammation [148, 149]. Exogenous infusions of soluble NTPDases are able to rescue Entpd1-deficient mice from systemic toxicity induced by ischemia reperfusion injury and after stroke induction [145, 150].
Angiogenesis requires the dynamic interaction of endothelial cell proliferation and differentiation with orchestrated interactions between extracellular matrix and surrounding cells (such as vascular smooth muscle and/or pericytes) [151, 152, 153]. NTPDase1 appears crucial in the co-ordination of angiogenic responses in inflammation, organ remodeling and transplantation [20, 134]. For example, in syngeneic pancreatic islet transplantation, the maintenance and revascularization of grafted islets appears dependent upon expression of NTPDase1 by the developing vasculature within the islet (Fig. 4).
In summary, multiple experimental studies largely reveal beneficial effects of over-expression of NTPDases within the vasculature, or by their pharmacological administration [20, 133]. Clinical studies of these soluble thromboregulatory factors are in planning [20, 154, 155].
There are multiple P2X and P2Y receptor subtypes expressed by monocytes and dendritic cells, whereas lymphocytes express only P2Y receptors . NTPDase1/CD39 was first described as a B lymphocyte activation marker and also shown to be expressed on activated T cells [156, 157] and dendritic cells . The CD39 enzymatic function on dendritic cells is involved in the recruitment, activation and polarization of naive T cells. ATP is released by CD4+ and CD8+ T cells upon stimulation with Con A or anti-CD3 mAb while CD39 functions as an additional recognition structure on haptenated target immunocytes for HLA-A1-restricted, hapten-specific cytotoxic T cells [156, 157].
In cd39 null mice, there are major defects in dendritic cell function antigen presentation and T-cell responses to haptens (type IV hypersensitivity reactions) [19, 89]. Immunocyte-associated CD39 may play an immunoregulatory role by hydrolyzing ATP (and perhaps ADP) released by T cells during antigen presentation and thereby generating adenosine [19, 89, 158]. Ectoenzymes, including ectonucleotidases, are known to play an important role in leukocyte trafficking (for an excellent review on this topic, see ).
Recent work has indicated that regulatory CD4 + ve CD25 + ve T cells (Treg cells) play important roles in the maintenance of immunological reactivity and tolerance . The selective expression of CD39 by Treg and the question whether this ectonucleotidase and/or extracellular nucleotides influence(s) the function of these interesting cells is a focus of current work.
Digestive and renal systems
Released nucleotides are polarized and do not re-enter cells. They have to be transformed into the corresponding nucleosides that enter cells via specific transporters to rebuild nucleoside pools. If this did not occur, they would be lost from the metabolic pool. The same may pertain to dietary ingestion of nucleotides where NTPDases are potential participants in the digestion of exogenous nucleotides and intestinal function. In addition, extracellular nucleotide and adenosine receptors are highly expressed in the digestive and renal systems, so these molecules are likely to have homeostatic functions .
An important nucleotide-mediated mechanism that seems common to various epithelia, as well as to hepatocytes, involves the autocrine regulation of cell volume by ATP via P2 receptors [161, 162]. As P2 receptors are expressed by epithelia in a polarized manner and can be linked to several digestive and homeostatic functions [163, 164], the presence of NTPDases in the immediate environment may serve as regulatory switches.
In the liver, extracellular nucleotides are potentially involved in several functional contexts . There is evidence that extracellular nucleotides regulate glycogenolysis through activation of glycogen phosphorylase and inactivation of glycogen synthase by inhibition of the glucagon effect on cAMP and by the activation of phospholipase D [165, 166]. In addition, nucleotides may be involved in the regulation of canalicular contraction and bile flow [167, 168, 169]. Concentrations of canalicular adenine nucleotides in bile samples and effluents from hepatic cell lines are estimated to be around 0.1 to 5 µM [161, 168]. Hepatocytes and bile duct cells have been shown to interact and communicate via local ATP release in vitro . Extracellular ATP acts as a hepatic mitogen and activates JNK signaling and hepatocyte proliferation both in vitro and in vivo .
Several ectonucleotidases are expressed in liver. Of the nucleotide pyrophosphatase/phosphodiesterases, NPP1 (PC-1) is expressed on the basolateral membrane of hepatocytes while the closely related NPP3 (B10) has a predominant canalicular in distribution [172, 173]. NTPDase1 is highly expressed on larger vessels and more weakly on sinusoids as well as in Kupffer cells . In the quiescent liver, NTPDase2 is expressed by cells of the subendothelium of veins and adventitial cells of arteries, but not in sinusoids. In addition, NTPDase2 is expressed by portal fibroblasts near basolateral membranes of bile duct epithelia . Activated but not quiescent hepatic stellate cells express NTPDase2 at the protein level . Only low expression of NTPDase3 could be demonstrated at the mRNA level in the liver [50, 177].
NTPDase2 expression in portal fibroblasts, the primary fibroblastic cell type of the portal area, suggests a role in the regulation of bile ductular signaling and secretion [161, 175]. Jhandier et al. tested the hypothesis that portal fibroblast NTPDase2 regulates epithelial cell proliferation. Using co-cultures of cholangiocytes (Mz-ChA-1 human cholangiocarcinoma cells) and primary portal fibroblasts from rat liver, increased NTPDase2 expression decreased cell proliferation, and knockdown of NTPDase2 by siRNA increased proliferation. P2 receptor blockade also attenuated Mz-ChA-1 proliferation . These experiments defined a novel cross-talk signaling pathway between bile duct epithelial cells and underlying portal fibroblasts, regulated by NTPDase2. Because they are the chief fibrogenic cells of the liver, hepatic stellate cells and portal fibroblasts are important targets of liver disease therapy. Loss of NTPDase2 expression in human biliary cirrhosis, as well as in models of bile duct ligation in rat, has been observed. NTPDase2 expression also shifts from the portal area to bridging fibrous bands in cirrhosis with hepatitis C .
Functional ATPases were previously shown to be associated with bile canalicular plasma membranes by histochemical techniques ; the corresponding enzyme was subsequently incorrectly identified as cCAM105 [179, 180, 181]. More recent studies revealed that the canalicular ecto-ATPase corresponds to NTPDase8 , also referred to as hepatic ATP diphosphohydrolase (ATPDase) [174, 182]. NTPDase8 is the mammalian orthologue of the chicken ecto-ATPDase cloned from oviduct and liver [183, 184]. In tandem with ecto-5′-nucleotidase, NTPDase8 has the potential to regulate the concentration of nucleotides in the hepatic canalicule. The ultimate generation of extracellular adenosine from dephosphorylated ATP not only activates adenosine receptors but also produces the key molecule for purine salvage and consequent replenishment of ATP stores within many cell types [17, 185]. Adenosine transporters are of major importance to organs and cells incapable of de novo nucleotide synthesis such as brain, muscle, intestinal mucosa and bone marrow [167, 186]. As the liver appears to be a major source of purines for these tissues, curtailment of nucleotide loss into the bile may be important to maintain appropriate nucleotide/nucleoside concentrations within hepatocytes . Thus, dephosphorylation of nucleotides by ectonucleotidases may be critical for appropriate systemic purine homeostasis . The presence of NTPDase8, ecto-5′-nucleotidase and nucleoside transporters in the canalicular domain of hepatocytes would be consistent with an important role of NTPDase8 in purine salvage.
The exocrine pancreas
The exocrine pancreas secretes digestive enzymes and a HCO3-rich fluid. Acini release ATP and the excurrent ducts express several types of P2 receptors [187, 188]. Thus ATP may function as a paracrine mediator between pancreatic acini and ducts. Ectonucleotidase activity in pancreatic tissues was first detected in the rat in the 1960s [189, 190], followed by analyses in the pig [191, 192]. Cytochemical and biochemical observations have corroborated the association of ATPase activity with zymogen granules . In other studies of small intercalated/interlobular ducts, NTPDase1 immuno-fluorescence can be localized on the luminal membranes, while in larger ducts it is localized on the basolateral membranes . Upon stimulation with cholecystokinin octapeptide-8 (CCK-8), acinar NTPDase1 relocalized in clusters towards the lumen and is secreted into the pancreatic juice, as an active form associated with particulate fractions [188, 195]. As revealed by electron microscopy, NTPDase2 is located on epithelial cells, myoepithelial cells and the basolateral membrane of acini. Interestingly, NTPDase2 could be also detected at the basolateral surface of endothelial cells .
There are only few studies on the localization of NTPDases in salivary glands. NTPDases might play a role in the transport of electrolytes by modulating the extracellular ATP concentration in the salivary gland ducts. NTPDase1 reveals to be mainly vascular in expression. NTPDase2 was immunodetected on myoepithelial cells and in nerves [194, 196]. The immunolocalization of NTPDases 3 and 8 in salivary glands has not yet been determined.
The kidney reveals a complex cellular profile of expression for P1 and P2 receptors as well as of ectonucleotidases. Both ATP and adenosine have been invoked in the regulation of tubuloglomerular feedback [197, 198]. This feedback system links the salt concentrations in the tubular fluid at the macula densa to the vascular tone of the afferent arteriole of the same nephron. As depicted by their localization, NTPDases may participate in the regulation of several biological functions of the kidney, including vascular perfusion. In mouse, rat and porcine kidneys, NTPDase1 can be detected in vascular structures, including blood vessels of glomerular and peritubular capillaries [174, 199, 200]. NTPDase2 is detected on the Bowman’s capsules of mouse and rat  and NTPDase8 on the luminal side of porcine renal tubules . More recently, an immunohistochemical analysis of various ectonucleotidases of the rat nephron revealed expression of both NTPDase2 and NTPDase3 in the thick ascending limb, the distal tubule and the inner medullary collecting ducts. In addition, NTPDase3 is located in the cortical and outer medullary collecting ducts .
The nervous system
All cell types of the nervous system express nucleotide receptors . It is increasingly apparent that NTPDases are distributed in the nervous system as ubiquitously as are P2 receptors and that these ectoenzymes are directly involved in the control of P2 receptor function in nervous tissues [22, 31, 36]. Signaling via nucleotides is widespread both in the peripheral and central nervous system. Major nucleotide receptormediated functions in the central nervous system include the modulation of synaptic signal transmission , the propagation of Ca2+ waves between glial cells , or the control and activation of astrocytes and microglia [204, 205]. In addition, ATP can contribute to synaptic signal transmission . In the sympathetic nervous system, ATP acts as a fast neurotransmitter together with catecholamines , it is an important mediator of central and peripheral chemosensory transduction, including pain  and it is involved in the control of myelination formation of peripheral axons .
Central nervous system
ATP can be rapidly hydrolyzed to adenosine at brain synapses that in turn activates pre-or postsynaptic receptors, thereby modulating neuronal transmission. Adenine nucleotides undergo conversion to adenosine within a few hundred milliseconds in the extracellular (synaptic) space of rat brain slices [209, 210]. Complex synaptic interactions in the central nervous system may thus be modulated both by the activation of P2 and (after hydrolysis of the nucleotide) P1 receptors that may be located at identical or different cellular targets [202, 211].
Based on immunoblotting and in situ hybridization, NTPDase1, 2 and 3 are expressed in the mammalian brain [47, 57, 59, 116, 177, 212]. NTPDase1 and 2 have been purified from porcine brain [213, 214]. But the exact cellular allocation of individual subtypes is still a challenge. There is ample evidence from early enzyme histochemical investigations that surface-located catalytic activity for the hydrolysis of nucleoside tri-and diphosphates can be allocated to all cell types of the nervous system [for reviews see 22, 31, 36, 215]. This catalytic activity can be localized to synapses, including the synaptic cleft, at the surface of neurosecretory nerve terminals in the pituitary or at peripheral nerve terminals. These data imply a wide distribution of cell surface-located ATP hydrolyzing activity in the CNS.
Ecto-ATPase activity has been observed in synaptosomal fractions isolated from various sources, implying endogenous ectonucleotidase activity of nerve cells. Biochemical studies on isolated synaptosomes permit the determination of the ratios of ATP to ADP hydrolysis rates as well as the analysis of product formation. Total synaptosome fractions isolated from rat brain cortex and immunopurified cholinergic striatal synaptosomes revealed ratios of 3.4: 1 and 2.1: 1, respectively . ADP was found to transiently accumulate after addition of ATP, and was subsequently metabolized to AMP and adenosine. Similar results were obtained with hippocampal synaptosomes . This strongly argues against a major contribution by NTPDase1 and NTPDase2 and would rather be compatible with a neuronal expression of NTPDase3 (comp. Fig. 2). A recent immunocytochemical study allocates NTPDase3 to neurons including axon-like structures of various brain regions .
Astrocytes, oligodendrocytes, and microglia
The ratio of ATP to ADP hydrolysis is clearly different in cultured astrocytes. Astrocytes cultured from cortex or hippocampus display a ratio of 8: 1 . Furthermore, cultured rat cortical astrocytes accumulate ADP from ATP that is only very slowly further degraded to AMP . This would be largely compatible with NTPDase2 as the major ectonucleotidase of cultured astrocytes. Immunocytological investigations of adult rat and mouse brain sections assign NTPDase2 solely to the astrocyte-like stem cells in the subventricular zone of the lateral ventricles and the dentate gyrus of the hippocampus and to astrocytes in few distinct additional brain regions [221, 222]. Thus, cultured astrocytes may reveal functional properties that differ from the in situ situation as they tend to rapidly alter their protein expression profile .
Enzyme histochemistry assigns ecto-ATPase activity to both central and peripheral myelin , but fully supplementary immunocytochemical data are lacking. Enzyme histochemical staining for surface-located nucleoside diphosphate activity has long been used to identify microglia in tissue sections of the adult and developing brain . The major microglial ectonucleotidase has been identified as NTPDase1 .
Stem cells in the adult mammalian brain
Apparently, individual enzyme isoforms govern cell surface-located nucleotide hydrolysis in the various cell types of the central nervous system. This does not exclude however, the possibility that individual cell types express more than one isoform with one of the enzymes predominating. For example, PC12 cells express mRNA for NTPDase1-3. But the ATP/ADP hydrolysis ratio, the pattern of product formation and the immunocytochemical surface staining suggest that NTPDase3 is the major functional isoform [59, 228]. Similarly cultured normal and immortalized pituitary and hypothalamic cells express NTPDase1-3 . The future planned use of transgenic mice expressing fluorescent protein under the promoter of the respective NTPDase isoform will greatly facilitate the identification of the expression pattern of individual enzyme isoforms in the developing and adult nervous system.
Peripheral nervous system
Noradrenaline and ATP are co-released from sympathetic nerve terminals of the guinea pig heart whereby ATP enhances noradrenaline release by a mechanism controlled by ectonucleotidases, possibly NTPDase1 . Interestingly, stimulated sympathetic nerves of the guinea pig vas deferens release not only ATP and noradrenaline but also enzyme activity that degrades ATP to adenosine. The latter exhibits similarities to NTPDases and ecto-5′-nucleotidase but their molecular identity has not been defined .
NTPDase2 associates with immature and non-myelinating Schwann cells of peripheral nerves whereas NTPDase1 immunoreactivity is absent . NTPDase2 is also expressed by the satellite glial cells in dorsal root ganglia and sympathetic ganglia and by the enteric glia surrounding cell bodies of ganglionic neurons of the myenteric and submucous plexus .
The most comprehensive investigation of expression of NTPDases within sensory systems concerns the inner ear. Ectonucleotidase activity is associated with the tissues lining the perilymphatic compartment of the cochlea [232, 233]. Immunohistochemical analysis of the murine cochlea has assigned NTPDase1 to the cochlear vasculature and primary auditory neurons in the spiral ganglion, whereas NTPDase2 is associated with synaptic regions of the sensory inner and outer hair cells, supporting cells of the organ of Corti and additional tissue elements [234, 235]. Interestingly, noise exposure induces upregulation of NTPDase1 and NTPDase2 in the rat cochlea .
Taste buds transduce chemical signals in the mouth into neural messages. Taste cells and nerve fibers express P2X2 and P2X3 receptors  and various P2Y receptors [238, 239]. Genetic elimination of P2X2 and P2X3 receptors revealed that ATP is a key neurotransmitter in this system . NTPDase2 is expressed at the mRNA level in mouse taste papillae . Immunohistochemistry and enzyme histochemical staining allocate NTPDase2 to type I ‘glial-like’ cells in the tongue, palate and larynx. Furthermore, NTPDase2 immunostaining is associated with nearby nerves, suggestive of Schwann cells, implying that NTPDase2 may be a regulator in defined taste transmission.
The interruption of blood flow accompanied by an interrupted supply of oxygen and glucose initiates a sequence of events resulting in structural and functional damage of the nervous tissue, comparable to that seen at other sites of vascular injury . Transient global cerebral ischemia of the rat results in a long-term increase in extracellular nucleotide hydrolysis pathways [242, 243]. Preconditioning delays the postischemic increase in ATP diphosphohydrolase activity . During the days following transient forebrain ischemia, mRNA for NTPDase1 (but not of NTPDase2) and ecto-5′-nucleotidase becomes upregulated in the hippocampus , corresponding to the upregulation of the entire ectonucleotidase chain for the hydrolysis of ATP to adenosine. The data suggest that the increased expression of ectonucleotidases in the regions of damaged nerve cells is associated with activated glia, mainly microglia .
The upregulation of the ectonucleotidase chain is suggestive of an ischemia-induced increased and sustained cellular release of nucleotides. This could have several functional implications. Since microglial cells express the cytolytic P2X7 receptor [244, 245] the activity of these cells may be particularly endangered by increased levels of extracellular ATP. Enhanced activity of NTPDase1 may prevent activated microglia from overstimulation by ATP released from the injured tissue. Alternatively, microglial expression of NTPDase1 might contribute to preventing receptor desensitization on prolonged exposure to elevated ATP levels. The parallel increase in activity of ecto-5′-nucleotidase would facilitate the formation of the final hydrolysis product adenosine that exerts neuro-modulatory and immunomodulatory actions and contributes to the protection of neurons.
Alterations following plastic changes in the nervous system
Additional experiments, analyzing synaptosome fractions, suggest that changes in neural plasticity can be paralleled by changes in ecto-ATPase activity. Enzyme activity is reduced following avoidance learning  and status epilepticus [247, 248]. It is altered in two rat models of temporal lobe epilepsy , and on pentylenetetrazol kindling . Changes in synaptosomal ectonucleotidase activity have been implicated by a broad variety of additional treatments including acute caffeine treatment . Taken together, these experiments suggest that expression of ectonucleotidases can be altered following a variety of physiological or pathological stimuli, possibly together with that of purine receptors. Further work needs to define the enzyme subtypes involved and the mechanisms underlying the regulation of ectonucleotidase expression.
This review summarizes components of extracellular nucleotide-mediated signaling pathways that are impacted upon largely by the E-NTPDase family of ectonucleotidases. Modulated, distinct NTPDase expression appears to regulate nucleotide-mediated signaling in essentially every tissue, including the vasculature and of immune and nervous systems. For example, extracellular nucleotide-mediated vascular endothelial and accessory cell stimulation might have important consequences for platelet activation, thrombogenesis, angiogenesis, vascular remodeling and the metabolic milieu of the vasculature, in response to inflammatory stress and/or immune reactions.
Nucleotides are also of significant relevance for the communication of nerve cells and glial cells or in the reciprocal signaling between these cells. These purinergic mechanisms might also dictate pathological processes of the nervous system or following vascular injury, thromboregulatory disturbances, and defective angiogenesis with associated perturbations in tissue remodeling and regeneration.
There is a wide field for future investigations of the role of nucleotides and ectonucleotidases in other tissues. Increasing interest in this field may open up new avenues for investigation and the development of new treatment modalities for a large variety of diseases, including neurological pathological states, vascular thrombotic disorders including stoke, atherosclerosis and the vascular inflammation seen in transplant-graft failure.
This work was supported by the Deutsche Forschungsgemeinschaft (140/17-1; GRK 361; to HZ); NIH HL57307, HL63972 and HL076540 (to SCR), and the Canadian Institutes of Health Research (CIHR; to JS). JS is also a recipient of a New Investigator award from the CIHR.
- 3.Lazarowski ER (2003) Molecular and biological properties of P2Y receptors. In: Schwiebert EM (ed) Extracellular Nucleotides and Nucleosides: Release, Receptors, and Physiological and Pathophysiological Effects. Academic, Amsterdam, Boston, pp 59–96Google Scholar
- 5.Weisman GA, Erb L, Garrad RC et al (1998) P2Y nucleotide receptors in the immune system: Signaling by a P2Y2 receptor in U937 monocytes. Drug Dev Res 45:222–228Google Scholar
- 6.Erlinge D, You JP, Wahlestedt C et al (1995) Characterisation of an ATP receptor mediating mitogenesis in vascular smooth muscle cells. Eur J Pharmacol-Molec Pharm 289:135–149Google Scholar
- 18.Zimmermann H (1996) Extracellular purine metabolism. Drug Dev Res 39:337–352Google Scholar
- 19.Robson SC, Enjyoji K, Goepfert C et al (2001) Modulation of extracellular nucleotide-mediated signaling by CD39/nucleoside triphosphate diphosphohydrolase-1. Drug Dev Res 53:193–207Google Scholar
- 22.Zimmermann H (2001) Ecto-nucleotidases. In: Abbracchio MP, Williams M (eds) Handbook of experimental pharmacology. Purinergic and pyrimidergic signalling. Springer, Berlin Heidelberg New York, pp 209–250Google Scholar
- 28.Burch LH, Picher M (2006) E-NTPDases in human airways regulation and relevance for chronic lung diseases. Purinergic Signalling (PUSI 2:1; this issue)Google Scholar
- 29.Grinthal A, Guidotti G (2006) CD39, NTPDase1, is attached to the plasma membrane by two transmembrane domains. Why? Purinergic Signalling (PUSI 2:1; this issue)Google Scholar
- 30.Kirley TL, Crawford PA, Smith TM (2006) The structure of the nucleoside triphosphate diphosphohydrolases (NTPDases) as revealed by mutagenic and comptational modeling analyses. Purinergic Signalling (PUSI 2:1; this issue)Google Scholar
- 33.Zimmermann H (2000) Extracellular metabolism of ATP and other nucleotides. Naunyn–Schmiedeberg’s Arch Pharmacol 362:299–309Google Scholar
- 34.Zimmermann H (2001) Ectonucleotidases: Some recent developments and a note on nomenclature. Drug Dev Res 52:44–56Google Scholar
- 35.Wang TF, Handa M, Guidotti G (1998) Structure and function of ectoapyrase (CD39). Drug Dev Res 45:245–252Google Scholar
- 37.Pearson JD (1985) Ectonucleotidases. Measurememt of activities and use of inhibitors. In: Paton DM (ed) Methods in pharmacology 6. Plenum, New York, pp 83–107Google Scholar
- 38.Ziganshin AU, Hoyle CHV, Burnstock G (1994) Ecto-enzymes and metabolism of extracellular ATP. Drug Dev Res 32:134–146Google Scholar
- 39.Beaudoin AR, Sévigny J, Picher M (1996) ATP-diphosphohydrolases, apyrases, and nucleotide phosphohydrolases: Biochemical properties and functions. In: Lee AG (ed) Biomembranes. JAI, Greenwich, London, pp 369–401Google Scholar
- 40.Zimmermann H, Pearson J (1998) Extracellular metabolism of nucleotides and adenosine in the cardiovascular system. In: Burnstock G, Dobson JG, Liang BT et al (eds) Cardiovascular Biology of Purines. Kluwer, Dordrecht, Boston, London, pp 342–358Google Scholar
- 52.Bigonnesse F, Lévesque SA, Kukulski F et al (2004) Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-8. Biochemistry USA 43:5511–5519Google Scholar
- 56.Zimmermann H, Beaudoin AR, Bollen M et al (2000) Proposed nomenclature for two novel nucleotide hydrolyzing enzyme families expressed on the cell surface. In: vanDuffel L, Lemmens R (eds) Ecto-ATPases and related ectonucleotidases, Shaker BV, Maastricht, pp 1–8Google Scholar
- 59.Vorhoff T, Zimmermann H, Pelletier J et al (2005) Cloning and characterization of the ecto-nucleotidase NTPDase3 from rat brain: Predicted secondary structure and relation to members of the E-NTPDase family and actin. Purinergic Signaling 1:259–270Google Scholar
- 60.Heine P, Braun N, Sévigny J et al (2001) The C-terminal cysteine-rich region dictates specific catalytic properties in chimeras of the ecto-nucleotidases NTPDase1 and NTPDase2. Eur J Biochem 262:102–107Google Scholar
- 61.Grinthal A, Guidotti G (2004) Dynamic motions of CD39 transmembrane domains regulate and are regulated by the enzymatic active site. Biochemistry USA 43:13849–13858Google Scholar
- 63.Vasconcelos EG, Ferreira ST, de Carvalho TMU et al (1996) Partial purification and immunohistochemical localization of ATP diphosphohydrolase from Schistosoma mansoni — Immunological cross-reactivities with potato apyrase and Toxoplasma gondii nucleoside triphosphate hydrolase. J Biol Chem 271:22139–22145PubMedGoogle Scholar
- 64.Schulte am Esch J, Sévigny J, Kaczmarek E et al (1999) Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity. Biochemistry USA 38:2248–2258Google Scholar
- 65.Smith TM, Kirley TL (2000) Expression, characterization, and site-directed mutagenesis of a human E-type ATPase. In: vanDuffel L, Lemmens R (eds) Ecto-ATPases and Related Ectonucleotidases. Shaker BV, Maastricht, pp. 90–105Google Scholar
- 66.Hicks-Berger CA, Yang F, Smith TM et al (2001) The importance of histidine residues in human ecto-nucleoside triphosphate diphosphohydrolase-3 as determined by site-directed mutagenesis. BBA Protein Struct Mol Enzym 1547:72–81Google Scholar
- 67.Yang F, Hicks-Berger CA, Smith TM et al (2001) Site-directed mutagenesis of human nucleoside triphosphate diphosphohydrolase 3: The importance of residues in the apyrase conserved regions. Biochemistry USA 40:3943–3950Google Scholar
- 70.Smith TM, Kirley TL (1999) Site-directed mutagenesis of a human brain ecto-apyrase: Evidence that the E-type ATPases are related to the actin/heat shock 70/sugar kinase superfamily. Biochemistry USA 38:321–328Google Scholar
- 71.Ivanenkov VV, Murphy-Piedmonte DM, Kirley TL (2003) Bacterial expression, characterization, and disulfide bond determination of soluble human NTPDase6 (CD39L2) nucleotidase: Implications for structure and function. Biochemistry USA 42:11726–11735Google Scholar
- 72.Ivanenkov VV, Meller J, Kirley TL (2005) Characterization of disulfide bonds in human nucleoside triphosphate diphosphohydrolase 3 (NTPDase3): Implications for NTPDase structural modeling. Biochemistry USA 44:8998–9012Google Scholar
- 73.Stout JG, Kirley TL (1996) Control of cell membrane ecto-ATPase by oligomerization state: Intermolecular cross-linking modulates ATPase activity. Biochemistry USA 35:8289–8298Google Scholar
- 74.Carl SAL, Smith TM, Kirley TL (1998) Cross-linking induces homodimer formation and inhibits enzymatic activity of chicken stomach ecto-apyrase. Biochem Mol Biol Int 44:463–470Google Scholar
- 76.Smith TM, Kirley TL (1999) Glycosylation is essential for functional expression of a human brain ecto-apyrase. Biochemistry USA 38:1509–1516Google Scholar
- 77.Grinthal A, Guidotti G (2000) Substitution of His59 converts CD39 into an ADPase in a quarternary structure dependent manner. Biochemistry USA 39:9–16Google Scholar
- 79.Grinthal A, Guidotti G (2002) Transmembrane domains confer different substrate specificities and adenosine diphosphate hydrolysis mechanisms on CD39, CD39L1, and chimeras. Biochemistry USA 41:1947–1956Google Scholar
- 87.Dunphy JT, Linder ME (1998) Signalling functions of protein palmitoylation. Biochim Biophys Acta Mol Cell Biol Lipids 1436:245–261Google Scholar
- 100.Wiendl HS, Schneider C, Ogilvie A (1998) Nucleotide metabolizing ectoenzymes are upregulated in A431 cells periodically treated with cytostatic ATP leading to partial resistance without preventing apoptosis. Biochim Biophys Acta Mol Cell Res 1404:282–298Google Scholar
- 103.Kennedy C, Westfall TD, Sneddon P (1996) Modulation of purinergic neurotransmission by ecto-ATPase. Semin Neurosci 8:195–199Google Scholar
- 107.Beigi RD, Kertesy SB, Aquilina G et al (2003) Oxidized ATP (OATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Brit J Pharmacol 140:507–519Google Scholar
- 110.Hoffmann C, Heine P, Pradel G et al (2000) Inhibition of ecto-apyrase and ecto-ATPase by pyridoxal phosphate-related compounds. Drug Dev Res 51:153–158Google Scholar
- 119.Shaul PW, Anderson RGW (1998) Role of plasmalemmal caveolae in signal transduction. Am J Physiol — Lung Cell Mol Physiol 19:L843–L851Google Scholar
- 121.Weisman GA, Griffin K, Santiago-Perez LI et al (2001) P2Y2 receptors regulate multiple signal transduction pathways in monocytic cells. Drug Dev Res 53:186–192Google Scholar
- 122a.Wu Y, Sun X, Kaczmarek E et al (2006) Ran BPM associates with CD39 and modulates ecto-nucleotidase activity. Biochem J, Epub ahead of print.Google Scholar
- 124.Wu Y, Sun X, Enjyoji K et al (2004) NTPDase1 interacts with RanBPM to directly modulate Ras activation and cellular proliferation in liver regeneration following partial hepatectomy. Hepatology 135:222Google Scholar
- 125.Hall RA, Ostedgaard LS, Premont RT et al (1998) A C-terminal motif found in the β2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci U S A 95:8496–8501PubMedGoogle Scholar
- 129.North RA (1996) P2X purinoceptor plethora. Semin Neurosci 8:187–194Google Scholar
- 137.Mulero JJ, Yeung G, Nelken ST et al (1999) CD39-L4 is a secreted human apyrase, specific for the hydrolysis of nucleoside diphosphates. J Biol Chem 29:20064–20067Google Scholar
- 138.Robson SC, Sévigny J, Imai M et al (2000) Thromboregulatory potential of endothelial CD39/nucleoside triphosphate diphosphohydrolase: Modulation of purinergic signalling in platelets. Emerg Ther Targets 4:155–171Google Scholar
- 144.Giancotti F, Ruoslahti E (1999) Integrin signalling. Science 285:102–104Google Scholar
- 151.Diazflores L, Gutierrez R, Varela H (1994) Angiogenesis — An update. Histol Histopathol 9:807–843Google Scholar
- 168.Chari RS, Schutz SM, Haebig JE et al (1996) Adenosine nucleotides in bile. Am J Physiol Gastroin Liver Physiol 33:G246–G252Google Scholar
- 187.Novak I, Amstrup J, Henriksen KL et al (2003) ATP release and effects in pancreas. Drug Dev Res 59:128–135Google Scholar
- 193.Beaudoin AR, Laliberté JF, LeBel D et al (1980) Localization and physiological role of the ATP-diphosphohydrolase in the pancreatic acinar cell. In: Ribet A, Pradayrol L, Susini C (eds) Biology of normal and cancerous exocrine pancreatic cells. Elsevier, Elsevier, pp 273–318Google Scholar
- 196.Sévigny J, Grondin G, Gendron FP et al (1998) Demonstration and immunolocalization of ATP diphosphohydrolase in the pig digestive system. Am J Physiol Gastrointest Liver Physiol 38:G473–G482Google Scholar
- 201.Vekaria RM, Shirley DG, Sévigny J et al (2006) Immunolocalisation of ectonucleotidases along the rat nephron. Am J Physiol Renal Physiol 290:550–560Google Scholar
- 204.Weisman GA, Wang M, Kong Q et al (2005) Molecular determinants of P2Y2 nucleotide receptor function: Implications for proliferative and inflammatory pathways in astrocytes. Mol Neurobiol 31:1–15Google Scholar
- 206.Burnstock G (1995) Noradrenaline and ATP: Cotransmitters and neuromodulators. J Physiol Pharmacol 365–384Google Scholar
- 215.Nagy AK (1997) Ecto-ATPases of the nervous system. In: Plesner L, Kirley TL, Knowles AF (eds) Ecto-ATPases: Recent progress in structure and function. Plenum, New York, pp 1–13Google Scholar
- 224.Braun N, Zimmermann H (2001) Microglial ectonucleotidases: Identification and functional roles. Drug Dev Res 53:208–217Google Scholar
- 230.Mihaylova-Todorova ST, Todorov LD, Westfall DP (2002) Enzyme kinetics and pharmacological characterization of nucleotidases released from the guinea pig isolated vas deferens during nerve stimulation: Evidence for a soluble ecto-nucleoside triphosphate diphosphohydrolase-like ATPase and a soluble ecto-5’-nucleotidase-like AMPase. J Pharmacol Exp Ther 302:992–1001PubMedGoogle Scholar
- 241.Bartel DL, Sullivan SL, Lavoie ÉG et al (2006) Nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) is the ecto-ATPase of taste buds. J Comp Neurol 499 (in press)Google Scholar
- 243.Schetinger MRC, Bonan CD, Schierholt R et al (1998) Nucleotide hydrolysis in rats submitted to global cerebral ischemia: A possible link between preconditioning and adenosine production. J Stroke Cerebrovasc Dis 7:281–286Google Scholar
- 252.Mateo J, Harden TK, Boyer JL (1999) Functional expression of a cDNA encoding a human ecto-ATPase. Brit J Pharmacol 128:396–402Google Scholar
- 257.Yeung G, Mulero JJ, McGowan DW et al (2000) CD39L2, a gene encoding a human nucleoside diphosphatase, predominantly expresssed in the heart. Biochemistry USA 39:12916–12923Google Scholar